Advertisement
UK markets close in 6 hours 41 minutes

  • FTSE 100

    8,081.52
    +36.71 (+0.46%)
     

  • FTSE 250

    19,796.97
    -2.75 (-0.01%)
     

  • AIM

    755.52
    +0.65 (+0.09%)
     

  • GBP/EUR

    1.1631
    +0.0003 (+0.03%)
     

  • GBP/USD

    1.2426
    -0.0026 (-0.21%)
     

  • Bitcoin GBP

    53,611.62
    +352.35 (+0.66%)
     

  • CMC Crypto 200

    1,438.06
    +13.96 (+0.98%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CRUDE OIL

    82.96
    -0.40 (-0.48%)
     

  • GOLD FUTURES

    2,330.90
    -11.20 (-0.48%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     

  • DAX

    18,200.82
    +63.17 (+0.35%)
     

  • CAC 40

    8,121.14
    +15.36 (+0.19%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

Canada competition bureau approves GlaxoSmithKline/Novartis deal

Reuters - UK Focus

OTTAWA, Feb 23 (Reuters) - Canada's Competition Bureau on Monday approved a deal between GlaxoSmithKline PLC (Other OTC: GLAXF - news) and Novartis AG (LSE: 0QLR.L - news) , noting in a statement that U.S. authorities had already said the transaction could go ahead.

The companies agreed last April to the transaction that includes GSK buying Novartis' vaccines business, Novartis purchasing GSK's cancer drugs, and the two groups tying up in consumer healthcare. (Reporting by David Ljunggren)